The nuclear factor kappa B (NFkB) pathway controls a variety of processes, including inflammation, and thus, the regulation of NFkB has been a continued focus of study. Here, we report a newly identified regulation of this pathway, involving direct binding of the transcription factor NFkB1 (the p105 subunit of NFkB) to the C-terminus of the A 2B adenosine receptor (A 2B AR), independent of ligand activation. Intriguingly, binding of A 2B AR to specific sites on p105 prevents polyubiquitylation and degradation of p105 protein. Ectopic expression of the A 2B AR increases p105 levels and inhibits NFkB activation, whereas p105 protein levels are reduced in cells from A 2B AR-knockout mice. In accordance with the known regulation of expression of anti-and pro-inflammatory cytokines by p105, A 2B AR-null mice generate less interleukin (IL)-10, and more IL-12 and tumor necrosis factor (TNF-a). Taken together, our results show that the A 2B AR inhibits NFkB activation by physically interacting with p105, thereby blocking its polyubiquitylation and degradation. Our findings unveil a surprising function for the A 2B AR, and provide a novel mechanistic insight into the control of the NFkB pathway and inflammation.
Introduction
Extracellular adenosine elicits a wide array of physiological and pathological responses via binding to its four subtypes of cell surface receptors A 1 , A 2A , A 2B and A 3 , each of which has a unique pharmacological profile, tissue distribution and effector coupling. Adenosine receptors are typical G protein coupled receptors (GPCRs), which transmit signals through adenylyl cyclase/cAMP and phospholipase C/Ca 2+ pathways. It has been well documented that these receptors play important parts in the regulation of inflammation. Depending on the receptor subtype, they may exert anti-or/and pro-inflammatory effects. The A 2B adenosine receptor (A 2B AR) is a low-affinity adenosine receptor, expressed in immune cells, endothelial cells, aortic vascular smooth muscle, cecum, large intestine and urinary bladder (Yaar et al., 2005) . Considering its low affinity in some cases (Schulte and Fredholm, 2000; Schulte and Fredholm, 2003) , the A 2B AR was hypothesized to play important roles under inflammation and cell stress/damage conditions, where extracellular adenosine is drastically increased (Fredholm, 2007) . Interestingly, A 2B AR protein level could be selectively upregulated as a result of inflammation, injury, hypoxia and other types of cell stresses (Fredholm et al., 2001; Hart et al., 2009; Kolachala et al., 2005; Kong et al., 2006; Xaus et al., 1999) . However, there seems to be no consensus regarding the exact role of A 2B AR in the regulation of inflammation (Ryzhov et al., 2008a) .
NFkB is a ubiquitously expressed transcription factor regulating various biological functions, including inflammation. Mammalian cells express five NFkB members, including NFkB1 (p50 and its precursor p105), NFkB2 (p52 and its precursor p100), RelA (p65), RelB and c-Rel. Five NFkB inhibitory proteins have been described: IkBa, b and c as well as p100 and p105 (Hayden and Ghosh, 2004) . In resting cells, p105, like other IkB proteins, sequesters NFkB dimers into the cytoplasm. In response to stimulation, p105 is completely degraded by the proteasome, releasing NFkB dimers to translocate into the nucleus and regulate expression of target genes (Pereira and Oakley, 2008) . Previous work indicated that p105 plays a pivotal role in immune responses. Deletion of p105 in mice caused severe inflammation and increased susceptibility to opportunistic infections, indicating p105 as a suppressor of inflammation (Ishikawa et al., 1998) .
In the present study, we report that the A 2B AR directly binds to NFkB1/p105. Our in vitro and in vivo experiments demonstrated that A 2B AR binding stabilizes p105 protein by blocking its polyubiquitylation, thereby inhibiting the NFkB signaling pathway. Our study is the first to report that a GPCR directly interacts with p105, thereby identifying a new, unexpected regulator of the NFkB pathway.
Results

NFkB1/p105 binds to A 2B AR C-terminus domain in yeast two-hybrid assays
In order to better understand A 2B AR function, we searched for novel protein binding partners of A 2B AR by the yeast two-hybrid (YTH) screening assay, using a human lung cDNA library with the C-terminal 40 amino acids of the A 2B AR (A 2B AR-C) as a bait. Out of three million screened transformants, 26 positive clones were obtained, of which 20 positive clones encode p105. These results were verified by retransforming yeast with p105 and A 2B AR-C (Fig. 1A) . Non-identical, overlapping sequences of the positive clones suggested that the high frequency hit was not an artifact of over-amplification of a particular p105 segment in the library, but rather reflected a possible strong interaction of A 2B AR and p105.
To further determine the A 2B AR binding site of p105, we constructed various p105 deletion mutants (Fig. 1B) . The deletion of the N-terminal amino acids 1-542 or C-terminal PEST domain of p105 completely disrupted its interaction with A 2B AR-C in the YTH assay. In contrast, p105 fragments containing amino acids 497-542 and PEST domain bound to A 2B AR-C as well as the full-length p105 (Fig. 1B) . Thus, the PEST domain and residues 497-542 appear to be essential for the interaction with A 2B AR.
In addition, a series of A 2B AR-C deletion mutants were constructed to assess the p105 binding site. A 2B AR-CD [292] [293] [294] [295] [296] [297] [298] [299] [300] [301] [302] and A 2B AR-CD 292-312 lost their ability to interact with p105 ( Fig. 1C) . In contrast, the C-terminal deletion mutants A 2B AR-CD 312-332 and A 2B were still associated with p105 to an extent comparable to the intact A 2B AR-C. These data indicated that amino acids 292-302 of A 2B AR are necessary, and amino acids 292-312 are sufficient for p105 binding.
Association of A 2B adenosine receptor and p105 in mammalian cells
To further confirm A 2B AR-p105 interaction, we tested their physical binding by pull-down assays. The full length A 2B AR and A 2B AR-C were fused to glutathione S-transferase (GST) to generate GST-A 2B and GST-A 2B -C, respectively. GST-A 2B and GST-A 2B -C, but not GST alone, efficiently retained endogenous p105 ( Fig. 2A, left panel) . Reciprocal pull-down assays showed that GST-p105 and GST-p105-C (p105 without p50 region, amino acid residues 433-968), but not GST-p50 or GST alone, pulled down the V5-tagged A 2B AR ( Fig. 2A, right panel) . The results of GST-p105-C are consistent with the yeast mapping data in Fig. 1B .
A 2B AR-p105 interaction was further verified by coimmunoprecipitation assays in HEK293T cells, using a tagged-A 2B AR because of the lack of a reliable anti-A 2B AR antibody (supplementary material Fig. S1 ). Cell extracts of HEK293T cells transfected with V5-tagged A 2B AR were immunoprecipitated with an anti-V5 antibody. Endogenous p105 coprecipitated with A 2B AR, whereas no immunoreactive material was detected from cells transfected with mock vector pcDNA4-V5 (Fig. 2B , left panel). In a reciprocal experiment, V5-tagged p105 was expressed with Flag-tagged A 2B AR in HEK293T cells, followed by immunoprecipitation. A 2B AR was co-immunoprecipitated by anti-V5 antibody but not by control mouse IgG (Fig. 2B , right panel). Taken together, these results indicated that the A 2B AR and p105 are also capable of forming a complex in mammalian cells. In addition, the co-localization of A 2B AR and p105 was analyzed by confocal microscopy, in living cells to avoid shrinkage of the cytoplasm during the cell fixation process and therefore better assess the intracellular localization of A 2B AR, and in fixed cells to examine endogenous p105. A 2B AR-CFP was localized in both the plasmalemma and cytoplasm (Fig. 2C) , as has been observed for some other GPCRs . Importantly, A 2B AR-CFP were co-localized with p105-GFP or endogenous p105 in both the plasmlemma and cytoplasm (Fig. 2C) , consistent with the idea that A 2B AR and p105 physically interact in the cell.
Next, we asked whether A 2B AR-p105 association is dependent on A 2B AR agonist stimulation. At 24 h after transfection of V5-tagged A 2B AR, cells were treated with 10 mM N-ethyl carboxamidoadenosine (NECA), an A 2 -type adenosine receptor agonist. NECA, although eliciting a robust elevation of cAMP level (supplementary material Fig. S2 ), had little effect on A 2B AR-p105 interaction, arguing for an agonist-independent A 2B AR and p105 coupling (Fig. 2D) . It was noted that p105 protein level markedly increased in the presence of A 2B AR (Fig. 2B,D , also see Fig. 4 ).
Direct interaction of A 2B AR with p105
Although GST pull-down, co-immunoprecipitation and colocalization assays detected an association of A 2B AR and p105, these assays are incapable of distinguishing between direct protein-protein interactions and those mediated by an additional protein(s). Early studies suggested that b-arrestin physically interacts with p105 (Parameswaran et al., 2006) or A 2B AR (Matharu et al., 2001 ). To address whether p105-A 2B AR Fig. 1 . Identification of p105 as an A 2B AR-interacting protein in the YTH system. (A) Yeast colonies co-transformed with pDBLeu-A 2B AR-C and pPC86-p105 vectors were first grown on synthetic dropout plates lacking leucine and tryptophan (SD/Leu 2 Trp 2 ) to ensure successful cotransformation of the two vectors pDBLeu and pPC86, and subsequently were tested for the interaction of p105-A 2B AR-C by growing on synthetic dropout plates lacking leucine, tryptophan and histidine, supplemented with 50 mM 3-aminotriazole (SD/Leu 2 Trp 2 His 2 +50 mM 3-AT). pDBLeu-A 2B AR-C + pPC86, and pDBLeu + pPC86-p105 are negative controls. (B,C) Mapping the A 2B AR-binding region of p105 (B) and the p105-binding region of A 2B AR (C) with YTH assays. In B, yeasts were co-transformed with pDBLeu-A 2B -C (denoted as A2B-C) and different deletion mutants of p105, as indicated. In C, pPC86-p105 and deletion mutants of A 2B AR-C were co-transformed. +, growth; 2, no growth. Data shown in A-C are representative of three independent experiments. RHD, Rel homology domain; GRR, glycine-rich region; ANK, ankyrin repeats; DD, death domain; PEST, proline-, glutamicacid-, serine-and threonine-rich sequence.
association is mediated by b-arrestin or not, b-arrestin-null murine embryonic fibroblasts (MEFs) were used (supplementary material Fig. S3 ). Importantly, p105 interacted with the A 2B AR even in b-arrestin-null MEFs (Fig. 3A, right panel) . This observation demonstrated that b-arrestin is not necessary for p105-A 2B AR binding, although it does not rule out the involvement of b-arrestin in p105-A 2B AR interaction. To further exclude the presence of additional protein mediators of p105 and A 2B AR interaction, GST-p105 or GST-p105-C and maltose-binding protein (MBP)-tagged A 2B AR-C or MBP alone were purified from E. coli (supplementary material Fig. S4 ) and then used for pair-wise GST pull-down assays. Results showed that MBP-tagged A 2B AR-C, but not MBP alone, binds to p105 or p105-C ( Fig. 3B ; supplementary material Fig. S5 ), further strengthening the conclusion that A 2B AR-C-p105 interaction is independent of accessory protein(s).
A 2B AR stabilizes p105 by blocking its polyubiquitylationdependent degradation, resulting in suppression of NFkB activation Remarkably, the two A 2B AR binding sites of p105 (Fig. 1B) overlap with the potential ubiquitin ligase binding sites (Beinke 
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and Ley, 2004; Orian et al., 1999) . We reasoned that A 2B AR binding may interfere with p105 ubiquitylation and therefore regulate its stabilization. Indeed, ectopic expression of the A 2B AR dramatically increased endogenous p105 protein, while it had little impact on p105 mRNA level (Fig. 4A , also Fig. 2B,D) , indicating a post-transcriptional regulation. A 2B AR expression increased p105 protein expression in a dosedependent manner (Fig. 4B) . It was also noted that A 2B AR expression was accompanied by a reproducible increase in the level of p50 (Fig. 4A-C) , presumably secondary to augmented levels of p105 protein, which is processed into p50 (Beinke and Ley, 2004) . It has been well known that the overexpression of GPCRs without agonist stimulation mimics agonist-dependent activation of the receptors (Milano et al., 1994) . To exclude the possibility that the stabilizing effect of A 2B AR on p105 protein expression results from A 2B AR activation by A 2B AR overexpression, or by minimal adenosine present in the culture media, we examined the effect of NECA on p105 expression. NECA (10 mM) had no effect on p105 protein level ( Fig. 4C ; supplementary material Fig. S6 ), indicating that A 2B AR expression stabilizes p105 in an agonist-independent manner. In another set of experiments, we assessed p105 protein level after knocking down endogenous A 2B AR by siRNA. Knockdown of endogenous A 2B AR robustly reduced endogenous p105 protein level in resting cells (Fig. 4D) , but had no effect on p105 mRNA level (supplementary material Fig. S7 ).
In the canonical NFkB pathway, IkB kinase b (IKKb) induces quick degradation of p105 and activates NFkB signaling (Beinke and Ley, 2004) . We, thus, assessed A 2B AR-mediated p105 stabilization after p105 degradation was accelerated by the expression of IKKb-SS/EE, the constitutively active form of IKKb. The level of p105 was reduced by IKKb-SS/EE expression, as expected, and further decreased by A 2B AR knockdown (Fig. 4D) . Because amino acids 292-302 of A 2B AR are necessary for binding to p105 in YTH assays (Fig. 1C) , we generated a binding deficient mutant (A 2B ARD292-302) of A 2B AR by deleting amino acids 292-302. As expected, the mutation abolished the interaction of A 2B AR and p105 in HEK293T cells (Fig. 4E ). More importantly, the mutant failed to increase, even slightly decreased, p105 protein expression ( Fig. 4E) , demonstrating that the physical association with p105 is critical for the stabilizing effect of A 2B AR on p105.
In view of the fact that A 2B AR and ubiquitin ligases binding sites in p105 overlap (Fig. 1B) , we tested whether A 2B AR binding obstructs p105 ubiquitylation and thereby prevents ubiquitin-proteasome dependent degradation of p105. Significantly, A 2B AR expression markedly suppressed p105 polyubiquitylation (Fig. 5A) . MG132, the proteasome inhibitor, greatly elevated p105 polyubiquitylation, confirming that polyubiquitylated p105 is mostly, if not all, directed to the proteasome for degradation. In marked contrast, MG132 had little effect on p105 polyubiquitylation in the presence of A 2B AR expression, further supporting that the A 2B AR effectively blocks the proteasome-targeted ubiquitylation of p105. As control, the expression of another integral membrane protein cystic fibrosis transmembrane conductance regulator (CFTR) slightly increased p105 ubiquitylation, arguing against the possibility that the decrease in p105 polyubiquitylation upon A 2B AR expression is an artifact resulting from protein overexpression. It is well known that IKKb phosphorylates serines 927 and 933 in p105, triggering the ubiquitylation and subsequent degradation of p105. To test whether A 2B AR binding also affects p105 phosphorylation, we compared the phosphor-p105 (Serine 933) level in the presence or the absence of A 2B AR. A 2B AR had no effect on the phosphorylation level of p105 (Fig. 5B ), suggesting that A 2B AR specifically blocks the binding of ubiquitin ligases, but not IKKb, to p105. p105 acts as a NFkB-inhibitory protein, retaining p50, p65 or c-Rel in the cytoplasm and inhibiting NFkB signaling pathway. Our data showed that A 2B AR/p105 complex could interact with p65 and p50 (supplementary material Fig. S8 ). To examine the effect of A 2B AR-p105 interaction on NFkB activation, HEK293T cells were first transiently co-transfected with the V5-tagged A 2B AR and an NFkB-dependent luciferase reporter gene. A 2B AR expression modestly suppressed basal NFkB transcription activity, but this effect was much more profound in the presence of IKKb-SS/EE stimulation (Fig. 6A , left panel, see Discussion). CFTR, as a control, failed to alter NFkB activation. Moreover, NFkB activation was significantly increased by knocking down endogenous A 2B AR with siRNA treatment under both basal and IKKb-SS/EE induced conditions (Fig. 6A , right panel), supporting that endogenous A 2B AR expression inhibits NFkB signaling. These observations are further strengthened by the nuclear translocation assays using TransAM NFkB ELISA kit. Ectopic expression of the A 2B AR inhibited p65 and p50 nuclear translocation, especially with IKKb-SS/EE stimulation, while knocking down endogenous A 2B AR increased the nuclear translocation of p65 and p50 with or without IKKb-SS/EE. As control, A 2B AR did not change the nuclear translocation level of AP1 transcription factor c-Fos (Fig. 6B) . It is noted that in the absence of IKKb-SS/EE stimulation the inhibitory effect of ectopic A 2B AR expression on p65 and p50 nuclear translocation is small and not statistically significant, presumably because of the limited sensitivity of the assay.
p105 expression is reduced in A 2B AR2/2 mice Next, we examined the interrelation between A 2B AR and p105 expression in mice. We previously reported that the A 2B AR is expressed primarily or only in the vasculature of tissues, such as the pancreas, lung, and spleen. This was traced using bgalactosidase (b-gal) staining, as our A 2B AR knockout mice include b-gal-encoding gene under the control of the A 2B AR gene promoter, instead of the deleted A 2B AR gene (Yang et al., (Yang et al., 2006) . In accordance, A 2B AR deficiency is associated with reduced levels of p105 in the mesenteric artery (Fig. 7A ), but it does not induce a significant change in the basal level of p50 or p65 (supplementary material Fig. S9A ). Macrophages are also a significant site of expression of this receptor (Yang et al., 2006) . In these cells too p105 level is reduced compared to wild type (Fig. 7B) , with no significant changes in p50 or p65 (supplementary material Fig. S9B ). Finally, A 2B AR deficiency does not promote a change in the level of p105 in various tissues, which typically do not express significant levels of the A 2B AR (supplementary material Fig. S9C ). Lipopolysaccharide (LPS) upregulates the expression of the A 2B AR in various tissues (St Hilaire et al., 2008 ; and data not shown). Here, we show that p105 is downregulated in different tissues following in vivo administration of LPS into A 2B AR knockout mice, relative to wild-type mice (Fig. 7C ). As control, p65, p50 and IkBa expression levels did not change significantly between the control and KO samples. Taken together, these results are in line with our above-described biochemical studies, which showed that A 2B AR expression stabilizes the level of p105 protein.
Cytokines production in A 2B AR2/2 mice The expression of target genes of NFkB signaling was examined as additional functional evidence of reduced p105 expression in A 2B AR knockout mice. Numerous genes are modulated by NFkB signaling, however, we primarily focused on cytokine gene expression in order to better understand the role of A 2B AR in inflammation. Previous studies indicated that NFkB signaling regulates the production of numerous cytokines, including TNFa, IL-2, IL-6, IL-8 and IL-12 (Blackwell and Christman, 1997) . In addition, it was suggested that following LPS treatment p105/ p50 deficient mice produce more pro-inflammatory cytokines, such as TNF-a and IL-12, and less anti-inflammatory cytokines, including IL-10 (Cao et al., 2006) . Therefore, to define the impact of A 2B AR expression on p105-mediated NFkB signaling, we measured serum concentrations of TNF-a, IL-12 and IL-10 in LPS-treated A 2B AR knockout mice. A 2B AR deficiency resulted in 31% suppression of IL-10 and 35% elevation of TNF-a at 1 h, and 35% augmentation of IL-12 at 5 h after LPS stimulation (Fig. 8) . These results are consistent with data reported by Yang et al. (Yang et al., 2006) and support the notion that A 2B AR expression, in association with elevated p105 (Fig. 7) , regulates cytokine production, thereby suppressing inflammatory responses. Since adenosine is present at some level in different cellular milieus, we cannot conclude that some or all these effects in vivo are agonist-independent.
Discussion
Our study has unveiled a novel mechanistic insight into the control of the NFkB pathway and inflammation, and a surprising function of A 2B AR, a typical member of the GPCR family. This study is the first to report that a GPCR directly interacts with p105. We have shown that A 2B AR binds to p105 in regions overlapping with the ubiquitin ligase binding sites, and therefore sequesters p105 from polyubiquitylation and proteosome-dependent degradation, resulting in downregulation of NFkB signaling in an agonistindependent way. This agonist-independent A 2B AR regulation of NFkB signaling may have important biological implications, given that inflammation and cell stress selectively upregulate A 2B AR expression by 3-4 folds . The elevation of A 2B AR expression induced by inflammation could downregulate NFkB signaling and suppress inflammation, forming a negative feedback loop (summarized in supplementary material Fig. S10 ).
Emerging evidence suggests that GPCRs can also signal through G-protein independent pathways, although the classical paradigm of GPCR signaling involves interaction of ligand with the receptor, followed by G protein activation by the ligandbound receptor and modulation of intracellular signaling proteins, or targets. The effectors of the G-protein independent pathways include ion channels, and c-Src and Jak kinases (Liu et al., 2000) .
Although the present study is the first report of a Family A GPCR directly interacting with a transcriptional factor, two independent studies have previously found that the metabotropic GABA B receptor, a Family C GPCR, directly interacts with the transcription factors ATF4 (CREB2) and ATFx to modulate their cytosol-to-nucleus translocation, even though in an agonist-and G-protein-dependent manner (Nehring et al., 2000; White et al., 2000) . In addition, GABA B receptor also interacts with the transcription factor CCAAT/enhancer-binding protein (C/EBP) homologous protein (CHOP), resulting in reduced surface expression of the receptor (Sauter et al., 2005) . In our study, we addressed whether the physical and functional interaction between A 2B AR and p105 depends on A 2B AR agonist, as the interactions of GABA B and b2 adrenergic receptors with transcriptional factors are agonist-dependent (Gao et al., 2004; White et al., 2000) . Our data support an agonist-independent mechanism. Of note, however, in our experiments, we examined the effect of A 2B AR activation by NECA on the interaction of A 2B AR and p105, but not on NFkB activation per se. Our data suggest that NECA did not affect NFkB by altering the interaction of A 2B AR and p105, but the current study did not test whether or not the activation of A 2B AR could stimulate NFkB through other signaling pathways. We also examined the effect of A 2B AR-p105 interaction on A 2B AR function, considering that its interaction with the transcription factor CCAAT/enhancer-binding protein (C/EBP) homologous protein (CHOP) resulted in reduced surface expression of GABA B receptor (Sauter et al., 2005) . p105 expression did not seem to have any impact on A 2B AR-mediated cAMP generation (not shown).
It is well documented that GPCRs regulate NFkB signaling via activation of PKA, PKC and small GTPases (Diaz-Meco et al., 1994; Zhong et al., 1998) . A GPCR has recently been linked with IkBa and NFkB/p105 through arrestin (Gao et al., 2004; Parameswaran et al., 2006; Witherow et al., 2004) , which binds to ligand-bound GPCRs and mediates receptor endocytosis. Among the four isoforms of the arrestin family, two are expressed exclusively in the visual system, and the other two (b-arrestin 1 and 2) are ubiquitously expressed. It was suggested A 2B AR binds to and stabilizes p105 4513
Journal of Cell Science that arrestin directly bind to the DD/PEST domains of IkBa (Gao et al., 2004; Witherow et al., 2004) or p105 (Parameswaran et al., 2006) and prevents their phosphorylation and degradation. Interestingly, agonist stimulation of b2 adrenergic receptor enhances the interaction of arrestin and IkBa (Gao et al., 2004) . However, this effect could be mimicked neither by the stimulation of other GPCRs, such as d opioid receptor and bradykinin receptor, nor by stimulation of adenylyl cyclase (Gao et al., 2004) . The mechanism underlying this receptor-specific effect remains unknown. In view of these observations, we asked whether A 2B AR-p105 association is a direct protein-protein interaction or is also bridged by b-arrestin. By using b-arrestin null MEF cell lines, we demonstrated that the A 2B AR is able to bind to p105 directly.
The role of the A 2B AR in inflammation has been seemingly puzzling. Numerous pharmacological studies demonstrate that the activation of A 2B AR by adenosine triggers proinflammatory effects by upregulating proinflammatory cytokines and growth factors and downregulating anti-inflammatory cytokines in many cell types (Donoso et al., 2005; Feoktistov and Biaggioni, 1995; Fiebich et al., 1996; Rees et al., 2003; Ryzhov et al., 2004; Ryzhov et al., 2008a; Zhong et al., 2004) , while there is also some contradictory evidence, depending on the systems and conditions used (Eckle et al., 2008a; Eckle et al., 2008b ). Yang and colleagues showed that A 2B AR knockout mice display mild elevation of proinflammatory TNF-a and IL-6, and decreased levels of anti-inflammatory IL-10 in the plasma under basal conditions, and more so under LPS stimulation. This was associated with upregulation of the NFkB pathway (Yang et al., 2006) . These findings implied that the A 2B AR is constitutively activated by the basal concentration of adenosine. This was rather puzzling, considering that in some cellular systems the A 2B AR is only activated by high adenosine levels, occurring during cell/ tissue stress and damage (Fredholm, 2007) . The observation of Yang et al. (Yang et al., 2006) , pointing to an anti-inflammatory role of A 2B AR under basal conditions, was supported by a number of following studies in A 2B AR knockout mice (Csóka et Wild-type (WT) and A 2B AR knockout KO mice (n514) were injected with 10 mg/kg LPS intraperitoneally. After 1, 5 or 10 h, serum levels of IL-10 (A), TNF-a (B) and IL-12 (C) were examined with ELISA. For IL-10, *significantly different from wild-type mice, P 0 h 50.048; ***P 1 h 50.001; **P 10 h 50.006. For TNF-a, *P 1 h 50.039. For IL-12, **P 0 h 50.01 and P 5 h 50.002; ***P 1 h 50.0005; *P 10 h 50.044.
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Journal of Cell Science 2009; Grenz et al., 2008; Hart et al., 2009; Hua et al., 2007; Ryzhov et al., 2008b; Yang et al., 2008; Zhou et al., 2009 ). However, most of these studies did not scrutinize whether the basal phenotype in A 2B AR knockout mice resulted from loss of direct agonist activation, or rather an unidentified function of the A 2B AR. Ryzhov et al., (Ryzhov et al., 2008a) observed an increase in inflammatory indices under basal conditions (non LPS) in A 2B AR knockout mice compared to the wild type in the absence of adenosine stimulation, similar to the studies by Yang et al. (Yang et al., 2006) and other groups. Similar to the conclusion of these authors, we deduced that the A 2B AR can also exert an adenosine-independent downregulation of pro-inflammatory cytokines by associating with a previously unrecognized signaling pathway(s), identified in our current study. We also consider the report of direct regulation of expression of IL-10 by NFkB (Cao et al., 2006) . Our data suggest an alternative explanation of how the A 2B AR could regulate IL-10 production through A 2B AR-dependent NFkB signaling, in addition to the A 2B AR-p38-CREB pathway reported by Koscso et al. (Koscsó et al., 2012) .
In our in vivo experiments, no significant change in the basal protein level of p105 was observed in tissues from A 2B AR knockout mice in which the A 2B AR is typically poorly expressed, compared with wild-type mice. It is also possible that in in vivo resting cells p105 is ''inactive'' and sequesters NFkB dimer in the cytoplasm, and therefore, the protective effect of A 2B AR is not manifested. LPS effectively upregulates the expression of the A 2B AR (St Hilaire et al., 2008) . Upon LPS stimulation, most p105 is degraded in A 2B AR knockout mice, whereas in wild-type mice p105 levels are high, which would be expected if the A 2B AR prevents p105 polyubiquitylation and degradation. Of note, luciferase activity and nuclear translocation of p65 or p50, indicative of NFkB signaling was modestly downregulated upon ectopic expression of the A 2B AR, although p105 level was augmented. This is probably due to already saturating levels of p105 in the control cells prior to A 2B AR overexpression. Alternatively, the overexpression of A 2B AR activates the receptors without agonists, as it is well known that the overexpression of GPCRs without agonist stimulation mimics agonist-dependent activation of the receptors (Milano et al., 1994) . The activation of A 2B AR could stimulate NFkB signaling via PKA and PKC (Diaz-Meco et al., 1994; Zhong et al., 1998) , masking its agonist-independent protective effect on p105 in unstimulaled cells, and this masking effect is likely trivial when NFkB signaling is substantially activated by IKKb.
We consistently observed elevation of p50 level with p105 protein increase as a result of ectopic A 2B AR expression (Fig. 4A,B) . However, p105 decrease associated with either A 2B AR knock down/knockout or IKKb stimulation was not accompanied with a p50 decrease ( Fig. 4D; Fig. 7C ; supplementary material Fig. S9 ). It has been previously reported that decrease of p105 was not associated with any changes in basal p50 level (Heissmeyer et al., 2001) , suggesting that basal p50 is primarily generated through de novo synthesis (with co-translation of p105) ) and p105 processing into p50 is largely inhibited with docking of p50 under basal conditions . However, when p105 is upregulated post-translationally without accompanying p50 increase from co-translation, pre-existing level of p50 may not be sufficient to block p105 processing into p50 and therefore an increase of p50 will occur.
Finally, initial co-immunoprecipatation experiments indicated that p105 does not bind to the A 2A AR (data not shown). However, we cannot rule out the possibility that p105 interacts with other members of the adenosine receptor family. This could constitute a future line of investigations.
In sum, our study unveils novel mechanistic insights into the control of the NFkB pathway and inflammation. It is the first report to show that the A 2B AR negatively regulates NFkB activation by physically interacting with p105, thereby blocking its polyubiquitylation and degradation, with clear implications on NFkB-regulated pathways (supplementary material Fig. S10 ).
Materials and Methods
Mice
A 2B AR knockout mice were generated in an earlier study (Yang et al., 2006) and were backcrossed to C57BL/6J mice to reach a pure C57BL/6 background . Wild-type and A 2B AR knockout mice were strain-, sex-, and agematched (6-8 weeks old, unless otherwise indicated). All animal procedures were approved by the University Committee on Research Practices at Hong Kong University of Science and Technology.
Reagents and antibodies
Anti-p105, anti-p65, anti-IkBa, anti-HA, anti-b-actin and anti-GFP antibodies were from Santa Cruz, anti-NFkB1/p105 for immunostaining and anti-phospho-NFkB p105 (Ser933) from Cell Signaling, anti-V5 antibody from Invitrogen, anti-CFTR antibody from Chemicon, and anti-GST antibody from GE Healthcare (UK).
Plasmids
Human p105 cDNA was PCR amplified and subcloned into pcDNA4-V5 (Invitrogen). A 2B AR-pcDNA4-V5/Flag and pCFP-N1-A 2B AR vectors were generated by subcloning human A 2B AR cDNA from pRK5-A 2B AR (a gift from Dr S. V. Sitaraman). A 2B ARD292-302-pcDNA4-V5 was generated by deleting amino acids 292-302 from C-terminus of A 2B AR using overlapping extension PCR. Flag-tagged ubiquitin vector was provided by Drs. Gerd Walz and Yan Wang at University of Freiburg (Wang et al., 2007) . NFkB-dependent luciferase reporter vector and HA-tagged IKKb were from Z. W.'s lab. The constitutively active HAtagged IKKb (HA-IKKb-SS/EE) vector was generated using the QuickChange (Stratagene). pIRES2-EGFP-CFTR vector was obtained from Dr Xiandi Gong at Nanyang Technological University. For GST or Maltose-binding protein (MBP)-tagged recombinant plasmids, various proteins were subcloned into pGEX6p-1 (Amersham Pharmacia Biotech) or into pMAL-c5X vector (New England Biolabs). In yeast two-hybrid screens, various cDNA fragments of A 2B AR and p105 were constructed into pDBLeu and pPC86 (gifts from Dr Jun Xia at HKUST). All constructs were verified by DNA sequencing.
Yeast two-hybrid screen
Yeast two-hybrid screen was performed with the Matchmaker GAL4 Two-hybrid System (Clontech) and the human lung cDNA library (Invitrogen).
Cell culture and transfection
Wild-type and b-arrestin-null mouse embryonic fibroblast (MEF) cell lines (gifts from Dr R. J. Lefkowitz at Duke University) and HEK293T cells (ATCC CRL-11268 TM ) were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 units/ml penicillin/ streptomycin in an atmosphere of 95% air-5% CO 2 at 37˚C. All transfection were performed with Lipofectamine 2000 reagent kit (Invitrogen).
RNA isolation and RT-PCR
Total RNA was isolated from HEK293T cells with TRIZOLH reagents (Invitrogen). RT-PCR was performed with OneStep RT-PCR kits (Qiagen). The primer pairs used were as follows: for A 2B ARs, 59-CTCTTCCTCGCCTGCTTCGT-39 (sense) and 59-GGGCAGAACACACCCAAAGAA-39 (antisense) (expecting a 345 bp fragment); for p105, 59-ATGGCAGAAGATGATCCA-39 (sense) and 59-AAATTTTGCC-TTCTAGAGG-39 (antisense) (expecting a 2.9 kb fragment). b-actin was used as a loading control. The identities of the PCR products were confirmed by DNA sequencing. 
Pull down assays
After bound with GST or GST fusion proteins generated and purified from E. coli strain BL21, the glutathione Sepharose beads were loaded with cell lysates at 4˚C overnight, followed by 3 washes. The bound proteins were analyzed by western blotting. MBP-A 2B -C fusion protein was expressed in BL21 bacteria and purified by amylose resin kit (New England Biolabs).
Immunoprecipitation and western blotting
Approximately 100-200 mg of whole cell extracts were incubated with ,25 ml bed volume of protein A Sepharose beads (Santa Cruz) and 1 mg antibody. The total volume of the reaction was then adjusted to 400 ml with a CO-IP lysis buffer (HEPES 20 mM, NaCl 175 mM, NP-40 0.25%, glycerol 10%, EDTA 1 mM, DTT 1 mM, PMSF 1 mM, pH 7.6 adjusted with NaOH), supplemented with 16 Complete Protease Inhibitor cocktail (Roche). After incubation at 4˚C overnight, the beads were washed 3 times with 700 ml CO-IP lysis buffer. Then, the immunocomplexes were collected for western blotting, as previously described (Sun et al., 2008) . 
Ubiquitylation assays
At 48 h after transfection, HEK293T cells were pretreated with MG132 (10 mM) or DMSO for 3 h at 37˚C and lysed for 40 min in ubiquitylation lysis buffer A (8 M urea, 100 mM NaH 2 PO 4 , 1% Triton X-100, 10 mM Tris, pH 8.0). The supernatant was incubated with Ni 2+ -nitrilotriacetic acid-agarose (Qiagen) for 2 h. After washing twice with buffer A and twice with buffer B (same as buffer A except for 0.5% Triton X-100 and pH 6.3), the proteins were eluted twice with buffer C (same as buffer A except for 0.1% Triton X-100 and pH 4.5). All the procedures were performed at room temperature.
Luciferase reporter assays
HEK293T cells were co-transfected with 180 ng 36 NFkB luciferase reporter vector, 20 ng b-gal vector as an indicator of transfection efficiency, and 600 ng of various expression vectors. After 36-48 h, the supernatants of whole cell extracts were harvested for luciferase assays with a kit (Tropix, Bedford, MA) and luciferase activities were quantified by FLUOstar OPTIMA microplate reader (BMG Lab technologies, Germany) and normalized to parallel b-gal intensity to correct for differences in transfection efficiency. Protein concentration was measured using Bio-Rad DC Protein Assay (Bio-Rad Laboratories).
NFkB and AP1 activation assays
Nuclear proteins from HEK293T cells were prepared using the TransAM TM transcription assay kit (Active Motif). Nuclear extracts (5 mg; prepared as instructed by the manufacturer) were used to measure p65 and p50 nuclear translocation with TransAM TM NFkB Family kit, following the manufacturer's protocol. Nuclear c-Fos was analyzed with the TransAM TM AP1 c-Fos kit (Active Motif).
Mouse tissue isolation and cytokine assays
Mesenteric arteries were removed from A 2B AR KO and control 8-week-old male mice (strain-matched) and flash frozen. The tissue was homogenized and lysed on ice in radioimmunoprecipitation assay (RIPA) buffer A (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) with proteinase inhibitor cocktail. Lysates were vortexed for 10 min at 4˚C and then placed on ice for 30 min. The lysates were then frozen in liquid nitrogen and then thawed at 37˚C. This freeze-thaw cycle was repeated. The samples were centrifuged at 800 g for 10 min at 4˚C and the infranatant removed. This was repeated to clear the sample of all cell debris and remaining fat tissue. Following protein determination with the BioRad assay, samples were subjected to western blotting (75 mg/lane).
To upregulate the expression of the A 2B AR in other tissues, 6-8-week-old A 2B AR KO and wild-type mice were challenged with Lipopolysaccharides (LPS) administered intraperitoneally (10 mg/kg, Sigma 026:B6). For immunoblotting, mice were sacrificed 5 h after LPS treatment, different tissues were homogenized in RIPA buffer B (50 mM Tris-HCl, 1.0 mM EDTA, 150 mM NaCl, 0.1% SDS, 1% NP-40, 0.25% sodium deoxycholate, 1 mM PMSF, pH 7.4). After centrifugation at 16,000 g for 10 min, the supernatant was collected for immunoblot analysis. For cytokine assays, mouse serum was collected at different time points from 1-10 h after LPS challenge, a time frame in which cytokine release is maximal (Cao et al., 2006) . The levels of TNFa, IL-10, and IL-12 were measured using ELISA kits from eBioscience (San Diego, CA).
Peritoneal macrophage isolation
Peritoneal macrophages were collected from 12-week-old mice as non activated and seeded into plates at 1610 6 cells/ml in Macrophage serum free medium (Invitrogen, 12065), supplemented with 0.1% penicillin-streptomycin for 2 hours at 37˚C. Cells were then collected in RIPA buffer A (see above) for western blot analysis. This yields a low number of macrophages, all used for western blotting (50 mg protein/lane).
Quantification of western blots and statistics
Quantification of protein bands in western blots was carried out with ImageJ software. All data are expressed as means 6 SE. Unless indicated otherwise, Student's two-tailed t-test was used for statistical analysis. P,0.05 was considered as statistically significant. is ubiquitinized and completely degraded by the proteasome, releasing NFB dimers to translocate into the nucleus to regulate expression of target genes, which leads to inflammation and cell stress. Inflammation and cell stresses upregulate the expression of A 2B AR protein, which binds to p105 in regions overlapping with the ubiquitin ligase binding sites. This sequesters p105 from polyubiquitination and proteosome-dependent degradation, resulting in down-regulation of NFB signaling and suppression of inflammation in an agonist-independent way, forming a negative feedback loop.
A2B-
